Mangoceuticals Statistics
Total Valuation
Mangoceuticals has a market cap or net worth of $11.09 million. The enterprise value is $11.29 million.
Important Dates
The next estimated earnings date is Monday, March 31, 2025, after market close.
| Earnings Date | Mar 31, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Mangoceuticals has 2.56 million shares outstanding. The number of shares has increased by 70.22% in one year.
| Current Share Class | 2.56M |
| Shares Outstanding | 2.56M |
| Shares Change (YoY) | +70.22% |
| Shares Change (QoQ) | +15.74% |
| Owned by Insiders (%) | 29.80% |
| Owned by Institutions (%) | 3.07% |
| Float | 1.37M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.47 |
| Forward PS | n/a |
| PB Ratio | 0.69 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 14.95 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.07, with a Debt / Equity ratio of 0.02.
| Current Ratio | 0.07 |
| Quick Ratio | 0.05 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -17.44 |
Financial Efficiency
Return on equity (ROE) is -126.52% and return on invested capital (ROIC) is -66.80%.
| Return on Equity (ROE) | -126.52% |
| Return on Assets (ROA) | -61.78% |
| Return on Invested Capital (ROIC) | -66.80% |
| Return on Capital Employed (ROCE) | -60.44% |
| Revenue Per Employee | $251,667 |
| Profits Per Employee | -$3.11M |
| Employee Count | 3 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 17.97 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +28.30% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +28.30% |
| 50-Day Moving Average | 3.07 |
| 200-Day Moving Average | 3.89 |
| Relative Strength Index (RSI) | 58.08 |
| Average Volume (20 Days) | 163,800 |
Short Selling Information
The latest short interest is 37,317, so 1.46% of the outstanding shares have been sold short.
| Short Interest | 37,317 |
| Short Previous Month | 22,766 |
| Short % of Shares Out | 1.46% |
| Short % of Float | 2.73% |
| Short Ratio (days to cover) | 0.74 |
Income Statement
In the last 12 months, Mangoceuticals had revenue of $755,000 and -$9.33 million in losses. Loss per share was -$5.65.
| Revenue | 755,000 |
| Gross Profit | 442,444 |
| Operating Income | -8.10M |
| Pretax Income | -9.02M |
| Net Income | -9.33M |
| EBITDA | -8.08M |
| EBIT | -8.10M |
| Loss Per Share | -$5.65 |
Full Income StatementBalance Sheet
The company has $73,912 in cash and $269,007 in debt, giving a net cash position of -$195,095 or -$0.08 per share.
| Cash & Cash Equivalents | 73,912 |
| Total Debt | 269,007 |
| Net Cash | -195,095 |
| Net Cash Per Share | -$0.08 |
| Equity (Book Value) | 13.39M |
| Book Value Per Share | 6.27 |
| Working Capital | -1.29M |
Full Balance SheetCash Flow
| Operating Cash Flow | -5.43M |
| Capital Expenditures | n/a |
| Free Cash Flow | -5.43M |
| FCF Per Share | -$2.12 |
Full Cash Flow StatementMargins
| Gross Margin | 58.60% |
| Operating Margin | -1,072.70% |
| Pretax Margin | -1,235.32% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |